Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intracoronary Stro-3 mesenchymal precursor cells for anterior STEMI after PCI
NL-OMON45102Phase 2Active, not recruiting
- Sponsor
- Mesoblast Ltd
- Start
- May 2014
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of rexlemestrocel-l in myocardial infarction (MI) (3 arms), sponsored by Mesoblast Ltd. Primary endpoints: Feasibility of intracoronary infusion, Change in left ventricular end-systolic volume by cardiac MRI and 1 more. Started May 2014; status: active, not recruiting.
02
Drugs
rexlemestrocel-l
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on NL-OMON45102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45102.